KAJMY
Q4 2026 EPS Estimate
$0.64
Nov 17, 2026 · Reports before open
Revenue Estimate
$4.46B
FY2027E EPS$419.63
FY2028E EPS$443.80

No analyst ratings available

No analyst price targets available for KAJMY

Analyst coverage may not be available for this symbol

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-2.30%
EPS+12.44%
FY2028
Rev+7.67%
EPS+5.76%
FY2029
Rev+3.69%
EPS+13.36%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2027EFY2028EFY2029EFY2030EFY2031E
Revenue Avg$3.00T$3.23T$3.35T$3.48T$3.58T
Low$2.96T$3.11T$3.26T$3.38T$3.49T
High$3.07T$3.34T$3.45T$3.57T$3.68T
EBITDA Avg$342.11B$368.33B$381.93B$395.91B$407.85B
Low$337.40B$353.94B$371.68B$385.28B$396.90B
High$350.05B$380.09B$392.52B$406.88B$419.15B
EBIT Avg$308.87B$332.54B$344.82B$357.44B$368.22B
Low$304.62B$319.55B$335.56B$347.84B$358.33B
High$316.03B$343.16B$354.37B$367.34B$378.42B
Net Income Avg$195.92B$207.21B$234.88B$243.48B$261.26B
Low$189.09B$199.98B$226.68B$234.98B$252.14B
High$202.98B$214.67B$243.34B$252.25B$270.67B
EPS Avg$419.63$443.80$503.07$521.48$559.56
Low$404.99$428.31$485.51$503.28$540.04
High$434.75$459.79$521.19$540.27$579.72
Analysts (Rev / EPS)7 / 17 / 14 / 13 / 14 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027
Revenue Avg$720.85B$741.15B$899.84B$683.46B
Low$706.37B$702.55B$867.13B$658.62B
High$741.18B$761.33B$924.77B$702.40B
EBITDA Avg$82.08B$84.39B$102.46B$77.82B
Low$80.43B$79.99B$98.73B$74.99B
High$84.39B$86.69B$105.30B$79.98B
EBIT Avg$74.10B$76.19B$92.50B$70.26B
Low$72.61B$72.22B$89.14B$67.71B
High$76.19B$78.26B$95.07B$72.21B
Net Income Avg$47.60B$53.01B$59.90B$42.39B
Low$45.35B$50.50B$57.07B$40.39B
High$49.31B$54.92B$62.06B$43.92B
EPS Avg$102.45$114.09$128.92$91.25
Low$97.61$108.70$122.83$86.93
High$106.14$118.21$133.57$94.53
Analysts (Rev / EPS)3 / 13 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

No recent analyst actions

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.